As neurological disorders become a leading cause of illness and disability worldwide, affecting over one-third of the global population according to the World Health Organization, Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing a pipeline that spans both prescription therapies and consumer wellness products. The company’s flagship pharmaceutical subsidiary, Lucid Psycheceuticals Inc., is developing LUCID-MS, a patented new chemical entity aimed at an unmet need in multiple sclerosis (MS). Current MS drugs primarily manage symptoms but do not address loss of mobility and function, leaving patients with limited options to slow disease progression.
Quantum BioPharma has also expanded into the wellness market through its involvement with unbuzzd™, an innovative, clinically validated alcohol metabolism accelerator designed to help individuals sober up faster. This product targets the growing demand for solutions related to alcohol health and sobriety, offering a consumer-ready option that complements the company’s pharmaceutical efforts.
The company’s dual focus reflects a broader industry trend toward addressing neurodegeneration at a biological level rather than merely managing symptoms. With neurological conditions placing increasing pressure on healthcare systems globally, therapies that can protect neurons and preserve brain function are in high demand. LUCID-MS represents a potential breakthrough for MS patients, as it directly targets the underlying mechanisms of the disease, which could lead to improved outcomes in mobility and quality of life.
Quantum BioPharma’s presence in the wellness sector with unbuzzd™ also highlights the company’s strategy to diversify its revenue streams while addressing a different but related health concern: alcohol metabolism. The product’s clinical validation positions it as a science-backed option in a market where consumers are increasingly seeking evidence-based solutions.
Investors and stakeholders can find the latest updates and news regarding Quantum BioPharma in the company’s newsroom at https://ibn.fm/QNTM. The company cautions that forward-looking statements involve risks and uncertainties, as detailed in its SEC filings, including the Risk Factors section of its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Quantum BioPharma Advances Neurological Pipeline and Wellness Market with LUCID-MS and unbuzzd.